Impact of renin-angiotensin system in hepatocellular carcinoma

Current Cancer Drug Targets

Volumn 11, Issue 4, 2011, Pages 431-441

  Yoshiji, H ^a   Noguchi, R ^a   Ikenaka, Y ^a   Kaji, K ^a   Aihara, Y ^a   Fukui, H ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Angiotensin converting enzyme; Angiotensin II; Hepatocellular carcinoma; Vascular endothelial growth factor

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOGENESIS INHIBITOR; ANGIOTENSIN II; BRANCHED CHAIN AMINO ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERFERON; VASCULOTROPIN; VITAMIN K GROUP;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CHEMOPROPHYLAXIS; HUMAN; INSULIN RESISTANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; RENIN-ANGIOTENSIN SYSTEM;

EID: 79955605827     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911795538084     Document Type: Article

References (170)

1. Romanque, P.; Piguet, A. C.; Dufour, J. F. Targeting vessels to treat hepatocellular carcinoma. Clin. Sci. (Lond) 2008, 114 (7), 467-477.
2. Llovet, J. M.; Bruix, J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 2008, 48 Suppl 1, S20-37.
3. Minguez, B.; Tovar, V.; Chiang, D.; Villanueva, A.; Llovet, J. M. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr. Opin. Gastroenterol. 2009, 25 (3), 186-194.
4. Yang, J. D.; Roberts, L. R. Epidemiology and management of hepatocellular carcinoma. Infect. Dis. Clin. North Am. 2010, 24 (4), 899-919, viii.
5. Ikeda, K.; Arase, Y.; Saitoh, S.; Kobayashi, M.; Suzuki, Y.; Suzuki, F.; Tsubota, A.; Chayama, K.; Murashima, N.; Kumada, H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000, 32 (2), 228-232.
6. Nishiguchi, S.; Shiomi, S.; Nakatani, S.; Takeda, T.; Fukuda, K.; Tamori, A.; Habu, D.; Tanaka, T. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001, 357 (9251), 196-197.
7. Kudo, M.; Sakaguchi, Y.; Chung, H.; Hatanaka, K.; Hagiwara, S.; Ishikawa, E.; Takahashi, S.; Kitai, S.; Inoue, T.; Minami, Y.; Ueshima, K. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology 2007, 72 Suppl 1, 132-138.
8. Shiratori, Y.; Shiina, S.; Teratani, T.; Imamura, M.; Obi, S.; Sato, S.; Koike, Y.; Yoshida, H.; Omata, M. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann. Intern. Med. 2003, 138 (4), 299-306.
9. Carmeliet, P. Angiogenesis in health and disease. Nat. Med. 2003, 9 (6), 653-660.
10. Kerbel, R. S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000, 21 (3), 505-515.
11. Saaristo, A.; Karpanen, T.; Alitalo, K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000, 19 (53), 6122-6129.
12. Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358 (19), 2039-2049.
13. Mazzone, M. Novel alternatives for anti-angiogenetic therapy and therapeutic angiogenesis. Verh. K. Acad. Geneeskd. Belg. 2010, 72 (3-4), 165-175.
14. Ferrara, N. VEGF: an update on biological and therapeutic aspects. Curr. Opin. Biotechnol. 2000, 11 (6), 617-624.
15. Shibuya, M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct. Funct. 2001, 26 (1), 25-35.
16. Yancopoulos, G. D.; Davis, S.; Gale, N. W.; Rudge, J. S.; Wiegand, S. J.; Holash, J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407 (6801), 242-248.
17. Ferrara, N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top Microbiol. Immunol. 1999, 237, 1-30.
18. Karkkainen, M. J.; Petrova, T. V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000, 19 (49), 5598-5605.
19. Fong, G. H.; Rossant, J.; Gertsenstein, M.; Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376 (6535), 66-70.
20. Shalaby, F.; Rossant, J.; Yamaguchi, T. P.; Gertsenstein, M.; Wu, X. F.; Breitman, M. L.; Schuh, A. C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376 (6535), 62-66.
21. Kiselyov, A.; Balakin, K. V.; Tkachenko, S. E. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin. Investig. Drugs 2007, 16 (1), 83-107.
22. Chow, N. H.; Hsu, P. I.; Lin, X. Z.; Yang, H. B.; Chan, S. H.; Cheng, K. S.; Huang, S. M.; Su, I. J. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum. Pathol. 1997, 28 (6), 698-703.
23. Mise, M.; Arii, S.; Higashituji, H.; Furutani, M.; Niwano, M.; Harada, T.; Ishigami, S.; Toda, Y.; Nakayama, H.; Fukumoto, M.; Fujita, J.; Imamura, M. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996, 23 (3), 455-464.
24. Miura, H.; Miyazaki, T.; Kuroda, M.; Oka, T.; Machinami, R.; Kodama, T.; Shibuya, M.; Makuuchi, M.; Yazaki, Y.; Ohnishi, S. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J. Hepatol. 1997, 27 (5), 854-861.
25. Suzuki, K.; Hayashi, N.; Miyamoto, Y.; Yamamoto, M.; Ohkawa, K.; Ito, Y.; Sasaki, Y.; Yamaguchi, Y.; Nakase, H.; Noda, K.; Enomoto, N.; Arai, K.; Yamada, Y.; Yoshihara, H.; Tujimura, T.; Kawano, K.; Yoshikawa, K.; Kamada, T. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 1996, 56 (13), 3004-3009.
26. Yamaguchi, R.; Yano, H.; Nakashima, Y.; Ogasawara, S.; Higaki, K.; Akiba, J.; Hicklin, D. J.; Kojiro, M. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol. Rep. 2000, 7 (4), 725-729.
27. Yamaguchi, R.; Yano, H.; Iemura, A.; Ogasawara, S.; Haramaki, M.; Kojiro, M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998, 28 (1), 68-77.
28. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Yamazaki, M.; Kikukawa, M.; Tsujinoue, H.; Nakatani, T.; Fukui, H. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 1998, 28 (6), 1489-1496.
29. Kaseb, A. O.; Hanbali, A.; Cotant, M.; Hassan, M. M.; Wollner, I.; Philip, P. A. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 2009, 115 (21), 4895-4906.
30. Schoenleber, S. J.; Kurtz, D. M.; Talwalkar, J. A.; Roberts, L. R.; Gores, G. J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br. J. Cancer 2009, 100 (9), 1385-1392.
31. Kerbel, R. S. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J. Clin. Oncol. 2001, 19 (18 Suppl), 45S-51S.
32. Kerbel, R. S.; Viloria-Petit, A.; Klement, G.; Rak, J. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur. J. Cancer 2000, 36 (10), 1248-1257.
33. Ferrara, N.; Alitalo, K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 1999, 5 (12), 1359-1364.
34. Boehm, T.; Folkman, J.; Browder, T.; O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390 (6658), 404-407.
35. Kerbel, R. S. A cancer therapy resistant to resistance. Nature 1997, 390 (6658), 335-336.
36. Li, C. Y.; Shan, S.; Huang, Q.; Braun, R. D.; Lanzen, J.; Hu, K.; Lin, P.; Dewhirst, M. W. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J. Natl. Cancer Inst. 2000, 92 (2), 143-147.
37. Frachon, S.; Gouysse, G.; Dumorti, J.; Couvelard, A.; Nejjari, M.; Mion, F.; Berger, F.; Paliard, P.; Boillot, O.; Scoazec, J. Y. Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J. Hepatol. 2001, 34 (6), 850-857.
38. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Hicklin, D. J.; Wu, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Tsujinoue, H.; Masaki, T.; Fukui, H. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004, 39 (6), 1517-1524.
39. Wu, X. Z. New strategy of antiangiogenic therapy for hepatocellular carcinoma. Neoplasma 2008, 55 (6), 472-481.
40. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64 (19), 7099-7109.
41. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359 (4), 378-390.
42. Eskens, F. A.; Verweij, J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur. J. Cancer 2006, 42 (18), 3127-3139.
43. Verheul, H. M.; Pinedo, H. M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer 2007, 7 (6), 475-485.
44. Berenson, A. A cancer drug shows promise, at a price that many can't pay. The New York times 2006, A1, C2.
45. Dzau, V. J.; Gibbons, G. H.; Pratt, R. E. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991, 18 (4 Suppl), II100-105.
46. Ardaillou, R. Angiotensin II receptors. J. Am. Soc. Nephrol. 1999, 10 Suppl 11, S30-39.
47. Matsusaka, T.; Ichikawa, I. Biological functions of angiotensin and its receptors. Annu. Rev. Physiol. 1997, 59, 395-412.
48. Smith, G.; Missailidis, S. In Learning from cancer, 2009, pp 158-185.
49. Rockey, D. C.; Weisiger, R. A. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996, 24 (1), 233-240.
50. Helmy, A.; Jalan, R.; Newby, D. E.; Hayes, P. C.; Webb, D. J. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology 2000, 118 (3), 565-572.
51. Arroyo, V.; Bosch, J.; Mauri, M.; Ribera, F.; Navarro-Lopez, F.; Rodes, J. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur. J. Clin. Invest. 1981, 11 (3), 221-229.
52. Ballet, F.; Chretien, Y.; Rey, C.; Poupon, R. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J. Pharmacol. Exp. Ther. 1988, 244 (1), 283-289.
53. Garcia-Pagan, J. C.; Bosch, J.; Rodes, J. The role of vasoactive mediators in portal hypertension. Semin. Gastrointest. Dis. 1995, 6 (3), 140-147.
54. Fernandez, L. A.; Twickler, J.; Mead, A. Neovascularization produced by angiotensin II. J. Lab Clin. Med. 1985, 105 (2), 141-145.
55. Le Noble, F. A.; Hekking, J. W.; Van Straaten, H. W.; Slaaf, D. W.; Struyker Boudier, H. A. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur. J. Pharmacol. 1991, 195 (2), 305-306.
56. Heffelfinger, S. C. The renin angiotensin system in the regulation of angiogenesis. Curr. Pharm. Des. 2007, 13 (12), 1215-1229.
57. Yoshiji, H.; Noguchi, R.; Kaji, K.; Ikenaka, Y.; Shirai, Y.; Namisaki, T.; Kitade, M.; Tsujimoto, T.; Kawaratani, H.; Fukui, H. Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. J. Gastroenterol. 2010, 45 (4), 443-450.
58. 1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J. Hepatol. 2007, 46 (6), 1026-1033.
59. Ikura, Y.; Ohsawa, M.; Shirai, N.; Sugama, Y.; Fukushima, H.; Suekane, T.; Hirayama, M.; Ehara, S.; Naruko, T.; Ueda, M. Expression of angiotensin II type 1 receptor in human cirrhotic livers: Its relation to fibrosis and portal hypertension. Hepatol. Res. 2005, 32 (2), 107-116.
60. Iwata, K.; Sohda, T.; Irie, M.; Takeyama, Y.; Anan, A.; Shakado, S.; Sakisaka, S. Angiotensin II type 1 receptor antagonist improves the prognosis in rats displaying liver cirrhosis induced by a cholinedeficient diet. J. Gastrointestin. Liver Dis. 2008, 17 (1), 21-25.
61. Oakley, F.; Teoh, V.; Ching, A. S. G.; Bataller, R.; Colmenero, J.; Jonsson, J. R.; Eliopoulos, A. G.; Watson, M. R.; Manas, D.; Mann, D. A. Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology 2009, 136 (7), 2334-2344 e2331.
62. 1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring) 2008, 16 (4), 770-776.
63. Krishna, P.; Nakata, M.; Nakajima, T.; Kitajima, I.; Maruyama, I. Increased production of vascular endothelial growth factor (VEGF) by angiotensin II. Neurosci. Res. Commun. 1999, 25, 79-88.
64. Yoshiji, H.; Kuriyama, S.; Kawata, M.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Fukui, H. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 2001, 7 (4), 1073-1078.
65. Yoshiji, H.; Kuriyama, S.; Fukui, H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol. 2002, 23 (6), 348-356.
66. Yoshiji, H.; Kuriyama, S.; Fukui, H. Perindopril: possible use in cancer therapy. Anticancer Drugs 2002, 13 (3), 221-228.
67. Lever, A. F.; Hole, D. J.; Gillis, C. R.; McCallum, I. R.; McInnes, G. T.; MacKinnon, P. L.; Meredith, P. A.; Murray, L. S.; Reid, J. L.; Robertson, J. W. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998, 352 (9123), 179-184.
68. Friis, S.; Sorensen, H. T.; Mellemkjaer, L.; McLaughlin, J. K.; Nielsen, G. L.; Blot, W. J.; Olsen, J. H. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001, 92 (9), 2462-2470.
69. Christian, J. B.; Lapane, K. L.; Hume, A. L.; Eaton, C. B.; Weinstock, M. A. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J. Natl. Cancer Inst. 2008, 100 (17), 1223-1232.
70. Wilop, S.; von Hobe, S.; Crysandt, M.; Esser, A.; Osieka, R.; Jost, E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J. Cancer Res. Clin. Oncol. 2009, 135 (10), 1429-1435.
71. 2 receptor stimulation may halt progression of pheochromocytoma. Ann. N. Y. Acad. Sci. 2006, 1073, 436-443.
72. Uemura, H.; Hasumi, H.; Kawahara, T.; Sugiura, S.; Miyoshi, Y.; Nakaigawa, N.; Teranishi, J.; Noguchi, K.; Ishiguro, H.; Kubota, Y. Pilot study of angiotensin II receptor blocker in advanced hormonerefractory prostate cancer. Int. J. Clin. Oncol. / Jpn. Soc. Clin. Onc. 2005, 10 (6), 405-410.
73. Kardum, D.; Huskic, J.; Fabijanic, D.; Banic, M.; Buljevac, M.; Kujundzic, M.; Loncar, B. Activity of serum angiotensinconverting enzyme as a tumour marker of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 1999, 11 (11), 1209-1213.
74. Yoshiji, H.; Noguchi, R.; Ikenaka, Y.; Kitade, M.; Kaji, K.; Tsujimoto, T.; Uemura, M.; Fukui, H. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. Curr. Med. Chem. 2007, 14 (26), 2749-2754.
75. Yoshiji, H.; Kuriyama, S.; Noguchi, R.; Fukui, H. Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Curr. CancerDrug Targets 2004, 4 (7), 555-567.
76. Scappaticci, F. A.; Smith, R.; Pathak, A.; Schloss, D.; Lum, B.; Cao, Y.; Johnson, F.; Engleman, E.G.; Nolan, G.P. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol. Ther. 2001, 3 (2), 186-196.
77. Scappaticci, F. A. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 2002, 20 (18), 3906-3927.
78. Noguchi, R.; Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Mitoro, A.; Tsujinoue, H.; Imazu, H.; Masaki, T.; Fukui, H. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin. Cancer Res. 2003, 9 (16 Pt 1), 6038-6045.
79. Yanase, K.; Yoshiji, H.; Ikenaka, Y.; Noguchi, R.; Kitade, M.; Kaji, K.; Yoshii, J.; Namisaki, T.; Yamazaki, M.; Asada, K.; Tsujimoto, T.; Akahane, T.; Uemura, M.; Fukui, H. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol. Rep. 2007, 17 (2), 441-446.
80. Ohnuma, Y.; Toda, M.; Fujita, M.; Hosono, K.; Suzuki, T.; Ogawa, Y.; Amano, H.; Kitasato, H.; Hayakawa, K.; Majima, M. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression. Biomed. Pharmacother. 2009, 63 (2), 136-145.
81. Noguchi, R.; Yoshiji, H.; Ikenaka, Y.; Namisaki, T.; Kitade, M.; Kaji, K.; Yoshii, J.; Yanase, K.; Yamazaki, M.; Tsujimoto, T.; Kawaratani, H.; Fukui, H. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol. Rep. 2009, 22 (2), 355-360.
82. Bergers, G.; Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3 (6), 401-410.
83. Bergers, G.; Javaherian, K.; Lo, K. M.; Folkman, J.; Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999, 284 (5415), 808-812.
84. Bolontrade, M. F.; Stern, M. C.; Binder, R. L.; Zenklusen, J. C.; Gimenez-Conti, I. B.; Conti, C. J. Angiogenesis is an early event in the development of chemically induced skin tumors. Carcinogenesis 1998, 19 (12), 2107-2113.
85. Staton, C. A.; Chetwood, A. S.; Cameron, I. C.; Cross, S. S.; Brown, N. J.; Reed, M. W. The angiogenic switch occurs at the adenoma stage of the adenoma-carcinoma sequence in colorectal cancer. Gut 2007.
86. Yoshiji, H.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Yanase, K.; Tsujinoue, H.; Imazu, H.; Fukui, H. Suppression of the reninangiotensin system attenuates vascular endothelial growth factormediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int. J. Oncol. 2002, 20 (6), 1227-1231.
87. Yoshiji, H.; Kuriyama, S.; Noguchi, R.; Yoshii, J.; Ikenaka, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Masaki, T.; Fukui, H. Combination of vitamin K(2) and the angiotensinconverting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J. Hepatol. 2005, 42 (5), 687-693.
88. Yoshiji, H.; Noguchi, R.; Toyohara, M.; Ikenaka, Y.; Kitade, M.; Kaji, K.; Yamazaki, M.; Yamao, J.; Mitoro, A.; Sawai, M.; Yoshida, M.; Fujimoto, M.; Tsujimoto, T.; Kawaratani, H.; Uemura, M.; Fukui, H. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J. Hepatol. 2009, 51 (2), 315-321.
89. Yoshiji, H.; Noguchi, R.; Yamazaki, M.; Ikenaka, Y.; Sawai, M.; Ishikawa, M.; Kawaratani, H.; Mashitani, T.; Kitade, M.; Kaji, K.; Uemura, M.; Yamao, J.; Fujimoto, M.; Mitoro, A.; Toyohara, M.; Yoshida, M.; Fukui, H. Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis. World J. Gastroenterol. 2007, 13 (23), 3259-3261.
90. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1 (1), 27-31.
91. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407 (6801), 249-257.
92. Chaturvedi, N.; Sjolie, A. K.; Stephenson, J. M.; Abrahamian, H.; Keipes, M.; Castellarin, A.; Rogulja-Pepeonik, Z.; Fuller, J. H. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998, 351 (9095), 28-31.
93. Gilbert, R. E.; Kelly, D. J.; Cox, A. J.; Wilkinson-Berka, J. L.; Rumble, J. R.; Osicka, T. Panagiotopoulos, S.; Lee, V.; Hendrich, E. C.; Jerums, G.; Cooper, M. E. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000, 43, 1360-1367.
94. Otani, A.; Takagi, H.; Suzuma, K.; Honda, Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ. Res. 1998, 82 (5), 619-628.
95. Sjolie, A. K.; Klein, R.; Porta, M.; Orchard, T.; Fuller, J.; Parving, H. H.; Bilous, R.; Chaturvedi, N. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008, 372 (9647), 1385-1393.
96. Nacak, M.; Nacak, I.; Sanli, M.; Ozkur, M.; Pektas, M.; Aynacioglu, A. S. Association of angiotensin converting enzyme gene insertion/deletion polymorphism with lung cancer in Turkey. Cancer Genet. Cytogenet. 2010, 198 (1), 22-26.
97. Srivastava, K.; Srivastava, A.; Mittal, B. Angiotensin I-converting enzyme insertion/deletion polymorphism and increased risk of gall bladder cancer in women. DNA Cell Biol. 2010.
98. Kaji, K.; Yoshiji, H.; Kitade, M.; Ikenaka, Y.; Noguchi, R.; Yoshii, J.; Yanase, K.; Namisaki, T.; Yamazaki, M.; Moriya, K.; Tsujimoto, T.; Kawaratani, H.; Akahane, T.; Uemura, M.; Fukui, H. Impact of insulin resistance on the progression of chronic liver diseases. Int. J. Mol. Med. 2008, 22 (6), 801-808.
99. Kitade, M.; Yoshiji, H.; Kojima, H.; Ikenaka, Y.; Noguchi, R.; Kaji, K.; Yoshii, J.; Yanase, K.; Namisaki, T.; Asada, K.; Yamazaki, M.; Tsujimoto, T.; Akahane, T.; Uemura, M.; Fukui, H. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006, 44 (4), 983-991.
100. Kitade, M.; Yoshiji, H.; Kojima, H.; Ikenaka, Y.; Noguchi, R.; Kaji, K.; Yoshii, J.; Yanase, K.; Namisaki, T.; Yamazaki, M.; Tsujimoto, T.; Akahane, T.; Fukui, H. Neovascularization and oxidative stress in the progression of nonalcoholic steatohepatitis. Mol. Med. Rep. 2008, 1, 543-548.
101. Kitade, M.; Yoshiji, H.; Noguchi, R.; Ikenaka, Y.; Kaji, K.; Shirai, Y.; Yamazaki, M.; Uemura, M.; Yamao, J.; Fujimoto, M.; Mitoro, A.; Toyohara, M.; Sawai, M.; Yoshida, M.; Morioka, C.; Tsujimoto, T.; Kawaratani, H.; Fukui, H. Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. World J. Gastroenterol. 2009, 15 (41), 5193-5199.
102. Kahn, C. R. Insulin resistance, insulin insensitivity, and insulin unresponsiveness: a necessary distinction. Metabolism 1978, 27 (12 Suppl 2), 1893-1902.
103. Davila, J. A.; Morgan, R. O.; Shaib, Y.; McGlynn, K. A.; El-Serag, H. B. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005, 54 (4), 533-539.
104. El-Serag, H. B.; Tran, T.; Everhart, J. E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126 (2), 460-468.
105. Marchesini, G.; Bianchi, G.; Merli, M.; Amodio, P.; Panella, C.; Loguercio, C.; Rossi Fanelli, F.; Abbiati, R. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003, 124 (7), 1792-1801.
106. Muto, Y.; Sato, S.; Watanabe, A.; Moriwaki, H.; Suzuki, K.; Kato, A.; Kato, M.; Nakamura, T.; Higuchi, K.; Nishiguchi, S.; Kumada, H. Effects of oral branched-chain amino acid granules on eventfree survival in patients with liver cirrhosis. Clin. Gastroenterol. Hepatol. 2005, 3 (7), 705-713.
107. Muto, Y.; Sato, S.; Watanabe, A.; Moriwaki, H.; Suzuki, K.; Kato, A.; Kato, M.; Nakamura, T.; Higuchi, K.; Nishiguchi, S.; Kumada, H.; Ohashi, Y. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol. Res. 2006, 35 (3), 204-214.
108. Yoshiji, H.; Noguchi, R.; Kitade, M.; Kaji, K.; Ikenaka, Y.; Namisaki, T.; Yoshii, J.; Yanase, K.; Yamazaki, M.; Tsujimoto, T.; Akahane, T.; Kawaratani, H.; Uemura, M.; Fukui, H. Branchedchain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J. Gastroenterol. 2009, 44 (5), 483-491.
109. Nishitani, S.; Ijichi, C.; Takehana, K.; Fujitani, S.; Sonaka, I. Pharmacological activities of branched-chain amino acids: specificity of tissue and signal transduction. Biochem. Biophys. Res. Commun. 2004, 313 (2), 387-389.
110. Nishitani, S.; Takehana, K.; Fujitani, S.; Sonaka, I. Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288 (6), G1292-1300.
111. Kawaguchi, T.; Taniguchi, E.; Itou, M.; Sumie, S.; Oriishi, T.; Matsuoka, H.; Nagao, Y.; Sata, M. Branched-chain amino acids improve insulin resistance in patients with hepatitis C virus-related liver disease: report of two cases. Liver Int. 2007, 27 (9), 1287-1292.
112. Kawaguchi, T.; Nagao, Y.; Matsuoka, H.; Ide, T.; Sata, M. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int. J. Mol. Med. 2008, 22 (1), 105-112.
113. Tsuchiya, K.; Asahina, Y.; Sato, T.; Tanaka, I.; Hirayama, Y.; Yasui, N.; Komatsu, N.; Umeda, N.; Kurosaki, M.; Izumi, N. Oral supplementation with branched-chain amino acid (BCAA) improves survival and dcreases the third time recurrence after successful treatment of hepatocellular carcinoma (HCC). J. Hepatol. (EASL proceeding) 2009, 48 suppl No2, S160.
114. Olivares-Reyes, J. A.; Arellano-Plancarte, A.; Castillo-Hernandez, J. R. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol. Cell Endocrinol. 2009, 302 (2), 128-139.
115. Jayasooriya, A. P.; Mathai, M. L.; Walker, L. L.; Begg, D. P.; Denton, D. A.; Cameron-Smith, D.; Egan, G. F.; McKinley, M. J.; Rodger, P. D.; Sinclair, A. J.; Wark, J. D.; Weisinger, H. S.; Jois, M.; Weisinger, R. S. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc. Natl. Acad. Sci. U S A 2008, 105 (18), 6531-6536.
116. Yoshiji, H.; Noguchi, R.; Kaji, K.; Ikenaka, Y.; Shirai, Y.; Namisaki, T.; Kitade, M.; Tsujimoto, T.; Kawaratani, H.; Fukui, H. Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. J. Gastroenterol. 2009.
117. Gaddam, K. K.; Pimenta, E.; Husain, S.; Calhoun, D. A. Aldosterone and cardiovascular disease. Curr. Probl. Cardiol. 2009, 34 (2), 51-84.
118. Williams, G. H. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev. 2005, 10 (1), 7-13.
119. Funder, J. W. Minireview: Aldosterone and mineralocorticoid receptors: past, present, and future. Endocrinology 2010, 151 (11), 5098-5102.
120. Jeong, Y.; Chaupin, D.F.; Matsushita, K.; Yamakuchi, M.; Cameron, S. J.; Morrell, C. N.; Lowenstein, C. J. Aldosterone activates endothelial exocytosis. Proc. Natl. Acad. Sci. USA 2009, 106 (10), 3782-3787.
121. Kaji, K.; Yoshiji, H.; Kitade, M.; Ikenaka, Y.; Noguchi, R.; Shirai, Y.; Yoshii, J.; Yanase, K.; Namisaki, T.; Yamazaki, M.; Tsujimoto, T.; Kawaratani, H.; Fukui, H. Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. Hepatol. Res.: the official journal of the Japan Society of Hepatology 2010, 40 (5), 540-549.
122. Noguchi, R.; Yoshiji, H.; Ikenaka, Y.; Kaji, K.; Shirai, Y.; Aihara, Y.; Yamazaki, M.; Namisaki, T.; Kitade, M.; Yoshii, J.; Yanase, K.; Kawaratani, H.; Tsujimoto, T.; Fukui, H. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. Int. J. Mol. Med. 2010, 26 (3), 407-413.
123. Wilkinson-Berka, J. L.; Tan, G.; Jaworski, K.; Miller, A. G. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ. Res. 2009, 104 (1), 124-133.
124. Okita, K.; Sakaida, I.; Hino, K. Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 2002, 62 Suppl 1, 24-28.
125. Sakaida, I.; Hironaka, K.; Uchida, K.; Suzuki, C.; Kayano, K.; Okita, K. Fibrosis accelerates the development of enzyme-altered lesions in the rat liver. Hepatology 1998, 28 (5), 1247-1252.
126. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Yanase, K.; Namisaki, T.; Yamazaki, M.; Tsujinoue, H.; Imazu, H.; Fukui, H. Extracellular matrix remodeling may predominate over hepatocyte injury in hepatocellular carcinoma development. Onc. Rep. 2003, 10 (4), 957-962.
127. Boudreau, N.; Bissell, M. J. Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr. Opin. Cell Biol. 1998, 10 (5), 640-646.
128. Theret, N.; Musso, O.; Turlin, B.; Lotrian, D.; Bioulac-Sage, P.; Campion, J. P.; Boudjema, K.; Clement, B. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001, 34 (1), 82-88.
129. Kalluri, R.; Sukhatme, V. P. Fibrosis and angiogenesis. Curr. Opin. Nephrol. Hypertens. 2000, 9 (4), 413-418.
130. Friedman, S. L. Liver fibrosis-from bench to bedside. J. Hepatol. 2003, 38 Suppl 1, S38-53.
131. Friedman, S. L. Molecular mechanisms of hepatic fibrosis and principles of therapy. J. Gastroenterol. 1997, 32 (3), 424-430.
132. Friedman, S. L. Cytokines and fibrogenesis. Semin. Liver Dis. 1999, 19 (2), 129-140.
133. Bataller, R.; Gines, P.; Nicolas, J. M.; Gorbig, M. N.; Garcia-Ramallo, E.; Gasull, X.; Bosch, J.; Arroyo, V.; Rodes, J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000, 118 (6), 1149-1156.
134. Arthur, M. J.; Mann, D. A.; Iredale, J. P. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J. Gastroenterol. Hepatol. 1998, 13 Suppl, S33-38.
135. Arthur, M. J. Degradation of matrix proteins in liver fibrosis. Pathol. Res. Pract. 1994, 190 (9-10), 825-833.
136. Yoshiji, H. Anti-fibrotic therapy: Are matrix metalloproteinases friends or foes? Hepatol. Res. 2009, 39 (8), 748-750.
137. Iredale, J. P. Tissue inhibitors of metalloproteinases in liver fibrosis. Int. J. Biochem. Cell Biol. 1997, 29 (1), 43-54.
138. Iredale, J. P.; Benyon, R. C.; Arthur, M. J.; Ferris, W. F.; Alcolado, R.; Winwood, P. J.; Clark, N.; Murphy, G. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996, 24 (1), 176-184.
139. Iredale, J. P.; Goddard, S.; Murphy, G.; Benyon, R. C.; Arthur, M. J. Tissue inhibitor of metalloproteinase-I and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. Clin. Sci. (Colch) 1995, 89 (1), 75-81.
140. Nakatsukasa, H.; Ashida, K.; Higashi, T.; Ohguchi, S.; Tsuboi, S.; Hino, N.; Nouso, K.; Urabe, Y.; Kinugasa, N.; Yoshida, K.; Uematsu, S.; Ishizaki, M.; Kobayashi, Y.; Tsuji, T. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas. Hepatology 1996, 24 (1), 82-88.
141. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Yanase, K.; Namisaki, T.; Imazu, H.; Fukui, H. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002, 36 (4 Pt 1), 850-860.
142. Yoshiji, H.; Kuriyama, S.; Miyamoto, Y.; Thorgeirsson, U. P.; Gomez, D. E.; Kawata, M.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Tsujinoue, H.; Nakatani, T.; Thorgeirsson, S. S.; Fukui, H. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000, 32 (6), 1248-1254.
143. Murawaki, Y.; Ikuta, Y.; Idobe, Y.; Kitamura, Y.; Kawasaki, H. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J. Hepatol. 1997, 26 (6), 1213-1219.
144. Murawaki, Y.; Yamamoto, H.; Kawasaki, H.; Shima, H. Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma. Clin. Chim. Acta 1993, 218 (1), 47-58.
145. Yoshiji, H.; Kuriyama, S.; Fukui, H. Blockade of renin-angiotensin system in antifibrotic therapy. J. Gastroenterol. Hepatol. 2007, 22 Suppl 1, S93-95.
146. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Fukui, H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001, 34 (4 Pt 1), 745-750.
147. Ohishi, T.; Saito, H.; Tsusaka, K.; Toda, K.; Inagaki, H.; Hamada, Y.; Kumagai, N.; Atsukawa, K.; Ishii, H. Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol. Res. 2001, 21 (2), 147-158.
148. Paizis, G.; Gilbert, R. E.; Cooper, M. E.; Murthi, P.; Schembri, J. M.; Wu, L. L.; Rumble, J. R.; Kelly, D. J.; Tikellis, C.; Cox, A.; Smallwood, R. A.; Angus, P. W. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J. Hepatol. 2001, 35 (3), 376-385.
149. Jonsson, J. R.; Clouston, A. D.; Ando, Y.; Kelemen, L. I.; Horn, M. J.; Adamson, M. D.; Purdie, D. M.; Powell, E. E. Angiotensinconverting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001, 121 (1), 148-155.
150. Hirose, A.; Ono, M.; Saibara, T.; Nozaki, Y.; Masuda, K.; Yoshioka, A.; Takahashi, M.; Akisawa, N.; Iwasaki, S.; Oben, J. A.; Onishi, S. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007, 45 (6), 1375-1381.
151. Ueki, M.; Koda, M.; Yamamoto, S.; Matsunaga, Y.; Murawaki, Y. Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J. Gastroenterol. 2006, 41 (10), 996-1004.
152. Yoshiji, H.; Fukui, H. Renin-angiotensin system and progression of chronic liver diseases. J. Gastroenterol. 2006, 41 (10), 1020-1022.
153. Yoshiji, H.; Noguchi, R.; Ikenaka, Y.; Namisaki, T.; Kitade, M.; Kaji, K.; Shirai, Y.; Yoshii, J.; Yanase, K.; Yamazaki, M.; Tsujimoto, T.; Kawaratani, H.; Akahane, T.; Aihara, Y.; Fukui, H. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res. Notes 2009, 2, 70.
154. Terui, Y.; Saito, T.; Watanabe, H.; Togashi, H.; Kawata, S.; Kamada, Y.; Sakuta, S. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002, 36 (4 Pt 1), 1022.
155. Yokohama, S.; Yoneda, M.; Haneda, M.; Okamoto, S.; Okada, M.; Aso, K.; Hasegawa, T.; Tokusashi, Y.; Miyokawa, N.; Nakamura, K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40 (5), 1222-1225.
156. Georgescu, E. F.; Ionescu, R.; Niculescu, M.; Mogoanta, L.; Vancica, L. Angiotensin-receptor blockers as therapy for mild-tomoderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 2009, 15 (8), 942-954.
157. Ueki, M.; Koda, M.; Shimizu, T.; Mitsuta, A.; Yamamoto, T.; Murawaki, Y. Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: a prospective study. Hepatogastroenterology 2009, 56 (93), 1100-1104.
158. Corey, K. E.; Shah, N.; Misdraji, J.; Abu Dayyeh, B. K.; Zheng, H.; Bhan, A. K.; Chung, R. T. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 2009, 29 (5), 748-753.
159. Ota, T.; Takamura, T.; Kurita, S.; Matsuzawa, N.; Kita, Y.; Uno, M.; Akahori, H.; Misu, H.; Sakurai, M.; Zen, Y.; Nakanuma, Y.; Kaneko, S. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007, 132 (1), 282-293.
160. Liu, Z. The renin-angiotensin system and insulin resistance. Curr. Diabetes Rep. 2007, 7 (1), 34-42.
161. Rimola, A.; Londono, M. C.; Guevara, G.; Bruguera, M.; Navasa, M.; Forns, X.; Garcia-Retortillo, M.; Garcia-Valdecasas, J. C.; Rodes, J. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004, 78 (5), 686-691.
162. Yoshiji, H.; Kuriyama, S.; Noguchi, R.; Yoshii, J.; Ikenaka, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Tsujinoue, H.; Fukui, H. Combination of interferon-beta and angiotensinconverting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development. Liver Int. 2005, 25 (1), 153-161.
163. Yoshiji, H.; Noguchi, R.; Kuriyama, S.; Ikenaka, Y.; Yoshii, J.; Yanase, K.; Namisaki, T.; Kitade, M.; Masaki, T.; Fukui, H. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288 (5), G907-913.
164. Yoshiji, H.; Noguchi, R.; Kojima, H.; Ikenaka, Y.; Kitade, M.; Kaji, K.; Uemura, M.; Yamao, J.; Fujimoto, M.; Yamazaki, M.; Toyohara, M.; Mitoro, A.; Fukui, H. Interferon augments the antifibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C. World J. Gastroenterol. 2006, 12 (42), 6786-6791.
165. Yoshiji, H.; Kuriyama, S.; Noguchi, R.; Ikenaka, Y.; Kitade, M.; Kaji, K.; Yoshii, J.; Yanase, K.; Yamazaki, M.; Asada, K.; Tsujimoto, T.; Akahane, T.; Uemura, M.; Fukui, H. Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development. Hepatol. Res. 2006, 36 (2), 124-129.
166. Josephs, D. H.; Ross, P. J. Sorafenib in hepatocellular carcinoma. Br. J. Hosp. Med. (Lond.) 2010, 71 (8), 451-456.
167. Medeiros, R.; Vasconcelos, A.; Costa, S.; Pinto, D.; Lobo, F.; Morais, A.; Oliveira, J.; Lopes, C. Linkage of angiotensin Iconverting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J. Pathol. 2004, 202 (3), 330-335.
168. Powell, E. E.; Edwards-Smith, C. J.; Hay, J. L.; Clouston, A. D.; Crawford, D. H.; Shorthouse, C.; Purdie, D. M.; Jonsson, J. R. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000, 31 (4), 828-833.
169. Fabris, C.; Smirne, C.; Fangazio, S.; Toniutto, P.; Burlone, M.; Minisini, R.; Bitetto, D.; Falleti, E.; Cerutti, A.; Pirisi, M. Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C. Hepatol. Res. 2009, 39 (8), 795-804.
170. Yoneda, M.; Hotta, K.; Nozaki, Y.; Endo, H.; Uchiyama, T.; Mawatari, H.; Iida, H.; Kato, S.; Fujita, K.; Takahashi, H.; Kirikoshi, H.; Kobayashi, N.; Inamori, M.; Abe, Y.; Kubota, K.; Saito, S.; Maeyama, S.; Wada, K.; Nakajima, A. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int. 2009.